Veracyte VCYT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $264.79M+41.0% | $364.23M+51.4% | $317.21M+15.3% | $221.15M-6.7% | $187.77M-10.7% | ||
| $50.11M-6.8% | $44.66M-4.0% | $47.83M-2.0% | $50.81M+1.0% | $53.78M+15.2% | ||
| $522.18M+36.3% | $488.38M+31.2% | $449.22M+25.9% | $414.68M+29.1% | $383.15M+31.9% | ||
| $22.65M+0.5% | $22.19M-3.3% | $18.9M-10.8% | $18.55M-16.8% | $22.53M+4.5% | ||
| $767.15M+1.7% | $767.15M+2.9% | $767.15M+0.7% | $773.26M+2.8% | $754.27M+0.1% | ||
| $79.66M-6.9% | $82.95M-18.9% | $86.28M-9.5% | $89.61M-9.5% | $85.59M-16.8% | ||
| —— | —— | —— | —— | —— | ||
| $1.44B+9.2% | $1.41B+8.2% | $1.37B+7.3% | $1.34B+8.9% | $1.32B+9.6% | ||
| $6.91M-56.0% | $4.59M-46.8% | $5.51M-43.0% | $11.45M-5.3% | $15.71M+29.3% | ||
| $749K-56.3% | $1.16M-30.7% | $417K-79.5% | $1.45M-33.9% | $1.71M-34.2% | ||
| $56.12M-25.3% | $59.94M-23.8% | $72.15M+2.6% | $76.43M+5.7% | $75.13M+29.4% | ||
| $91.99M-23.6% | $96.44M-22.3% | $110.12M+11.3% | $123.05M+20.9% | $120.48M+48.0% | ||
| 125M0.0% | 125M+160,156% | 125M0.0% | 125M0.0% | 125M0.0% | ||
| -$348.92M+20.1% | -$377.63M+14.9% | -$418.78M+6.8% | -$437.92M+5.7% | -$436.94M+7.0% | ||
| $1.34B+12.5% | $1.31B+11.4% | $1.26B+6.9% | $1.22B+7.8% | $1.19B+6.8% | ||
| $1.44B+9.2% | $1.41B+8.2% | $1.37B+7.3% | $1.34B+8.9% | $1.32B+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Veracyte cover its short-term obligations?
- Its current ratio is 9.31 — current assets exceed current liabilities.
- Where does Veracyte's balance sheet data come from?
- Every line is extracted from Veracyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.